NASDAQ
GT Biopharma, Inc. (GTBP) has a free cash flow growth of 38.62% as of Friday, May 29, 2026. This represents a 368.91% increase compared to its 12-month average of -14.36%. Free cash flow growth tracks the year-over-year percentage change in cash generated after capital expenditures.
No price data available for this timeframe.